Aegerion Pharmaceuticals Prices Public Offering of Common Stock
News Jun 15, 2012
The net proceeds to Aegerion from this offering are expected to be approximately $47.3 million, after deducting underwriting discounts and commissions. The offering is expected to close on June 19, 2012, subject to customary closing conditions.
Jefferies & Company, Inc. and J.P. Morgan Securities LLC are acting as joint book-running managers in the offering. Leerink Swann LLC, Canaccord Genuity Inc., and Needham & Company, LLC are acting as co-managers for the offering. Aegerion has granted the underwriters a 30-day option to purchase up to an aggregate of 510,000 additional shares of common stock. Aegerion anticipates using the net proceeds from the offering to fund activities directed at gaining approval of its New Drug Application submission with the U.S. Food and Drug Administration and Marketing Authorization Application submission with the European Medicines Agency for lomitapide as a potential treatment for homozygous familial hypercholesteremia (HoFH), pre-commercial and commercial activities related to launching lomitapide in the United States, the European Union, in each case, if approved, and in any other countries where lomitapide is approved as a treatment for HoFH, expansion of operations in certain countries, and advancement of the clinical development of lomitapide as a potential treatment for pediatric and adolescent patients with HoFH and of adult patients with familial chylomicronemia, with any remainder to fund working capital, capital expenditures and to be used for general corporate purposes.
The securities described above are being offered by Aegerion pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement related to the offering has been filed with the SEC. A final prospectus related to the offering will be filed with the SEC. The preliminary prospectus is available, and the final prospectus will be available, on the SEC's website at http://www.sec.gov . In addition, copies of the preliminary prospectus supplement and the final prospectus, when available, may be obtained from Jefferies & Company, Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at 1-866-803-9204.
This release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
In a strategic search, scientists created and screened a library of 45,000 new compounds containing chemical elements of widely used immune system suppressants, and say they found one that may prevent reperfusion injury, a tissue-damaging and common complication of surgery, heart attack and stroke.READ MORE